Kenneth Algazy, MD
Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC
Kenneth Algazy, MD, is a Clinical Professor of Medicine at University of Pennsylvania School of Medicine. He is also a Section Chief in the Division of Hematology and Oncology at Philadelphia VA Medical Center. Dr. Algazy is involved in clinical trials in lung cancer, and interested in demographics and outcomes in cancer at the VA Medical Center and the state of Pennsylvania. He has clinical and research interest in lung cancer, as well as all hematology and medical oncology. Dr. Algazy was on the board and Executive Committee and President of the staff of 2 Hospitals. (This is me - Update Profile)
| Unspecified - present | Section Chief of Hematology and Oncology Philadelphia VA Medical Center |
|---|---|
| Unspecified - present | Clinical Professor of Medicine University of Pennsylvania School of Medicine - CC |
GLG Study Groups with Kenneth Algazy, MD(?)
| Study Group Name | Members |
|---|---|
| Multiple Myeloma Physicians | 158 |
| Oncologists who Treat Hematologic Malignancies (US) | 657 |
| Lung Cancer Oncologists (US) | 85 |
| Sutent Prescribers for RCC: Oncologists (US) | 41 |
GLG NewsSM
Analyses by Kenneth Algazy, MD(?)
Myriad Genetics Inc. went directly to the patients who then were tested whether the tests were indicated or paid for by insurers or out of their own pockets. If patients have "medical savings accts" as suggested by various political candidates, right or wrong patients will want it with this kind...
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.
An interesting randomized phase II trial of Gemzar (the current standard with Tarceva) vs imexon + Gemzar. BUT shouldn't it be compared to Gemzar/ Tarceva??
Approval will be base on the phase III INTEREST trial that showed in NSCLC that Iressa was "non-inferior" to standard chemotherapy after platinum therapy failure first line. Iressa was better tolerated and had an improved quality of life.
GLG InstituteSM Seminars with Kenneth Algazy, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Kenneth Algazy, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms